Ignore the noise of the daily prices, particularly in a volatile market.
If IHL-42X becomes a genuine drug for OSA then IHL will be valued according to that market opportunity and Resmed demonstrates what that’s potentially worth. Even if IHL captured a modest percentage of their market share it’s billions. Many billions.
And that’s just one of six indications being developed.
General discussion, page-13709
-
- There are more pages in this discussion • 6,307 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)